From 3ce80763ceb275493cf59fef54759b2a84396edc Mon Sep 17 00:00:00 2001 From: Teleo Agents Date: Mon, 16 Mar 2026 15:39:40 +0000 Subject: [PATCH] extract: 2025-11-06-trump-novo-lilly-glp1-price-deals-medicare Pentagon-Agent: Ganymede --- ...t cost impact inflationary through 2035.md | 6 ++++ ...ients-undermining-chronic-use-economics.md | 6 ++++ ...just-clinical-factors-drive-persistence.md | 6 ++++ ...-novo-lilly-glp1-price-deals-medicare.json | 32 +++++++++++++++++++ ...mp-novo-lilly-glp1-price-deals-medicare.md | 15 ++++++++- 5 files changed, 64 insertions(+), 1 deletion(-) create mode 100644 inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json diff --git a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md index 8958d793..2004090f 100644 --- a/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md +++ b/domains/health/GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md @@ -53,6 +53,12 @@ The BALANCE Model directly addresses the chronic use inflation problem by requir At net prices with 48% rebates, semaglutide achieves $32,219/QALY ICER, making it highly cost-effective. The Trump Medicare deal at $245/month (82% discount) would push ICER below $30K/QALY. The inflationary claim may need scope qualification: GLP-1s are inflationary at list prices but potentially cost-saving at negotiated net prices, and the price trajectory is declining faster than the 2035 projection anticipated. + +### Additional Evidence (challenge) +*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16* + +The Trump Administration's Medicare GLP-1 deal establishes $245/month pricing (82% below list) with narrow eligibility criteria requiring comorbidities (BMI ≥27 with prediabetes/CVD or BMI >30 with heart failure/hypertension/CKD). This targets ~10% of Medicare beneficiaries—specifically the high-risk population where downstream savings (24% kidney disease progression reduction, cardiovascular protection) offset drug costs under capitation. The narrow eligibility is the mechanism that changes the cost-effectiveness calculus: inflationary impact depends on population breadth, not just drug price. + --- Relevant Notes: diff --git a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md index 1f412e7f..e71c73f2 100644 --- a/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md +++ b/domains/health/glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md @@ -47,6 +47,12 @@ This data comes from commercially insured populations (younger, fewer comorbidit No data yet on whether payment model affects persistence—does being in an MA plan with care coordination improve adherence vs. fee-for-service? This is directly relevant to value-based care design. + +### Additional Evidence (extend) +*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16* + +The $50/month out-of-pocket maximum for Medicare beneficiaries (starting April 2026 for tirzepatide) removes most financial barriers to persistence for the eligible population. Lower-income patients show higher discontinuation rates, suggesting affordability drives persistence. The OOP cap may improve persistence rates specifically in Medicare, though this remains untested. + --- Relevant Notes: diff --git a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md index c8aa0341..b9259e3a 100644 --- a/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md +++ b/domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md @@ -37,6 +37,12 @@ At $245/month list price, even modest copays ($50-100/month) create a sustained The source does not provide granular income-stratified discontinuation rates, so the magnitude of the effect is unclear. It's possible income is a proxy for other factors (health literacy, access to care coordination, baseline health status) rather than affordability per se. + +### Additional Evidence (confirm) +*Source: [[2025-11-06-trump-novo-lilly-glp1-price-deals-medicare]] | Added: 2026-03-16* + +The Trump Administration deal establishes a $50/month out-of-pocket maximum for Medicare beneficiaries, explicitly targeting affordability as a persistence barrier. The $245/month Medicare price (down from ~$1,350) combined with the OOP cap is designed to address the affordability-driven discontinuation pattern observed in lower-income populations. + --- Relevant Notes: diff --git a/inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json b/inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json new file mode 100644 index 00000000..f1b26014 --- /dev/null +++ b/inbox/archive/.extraction-debug/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.json @@ -0,0 +1,32 @@ +{ + "rejected_claims": [ + { + "filename": "narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md", + "issues": [ + "missing_attribution_extractor" + ] + }, + { + "filename": "manufacturer-price-concessions-in-exchange-for-coverage-expansion-is-a-novel-policy-mechanism-bypassing-traditional-cms-rulemaking.md", + "issues": [ + "missing_attribution_extractor" + ] + } + ], + "validation_stats": { + "total": 2, + "kept": 0, + "fixed": 2, + "rejected": 2, + "fixes_applied": [ + "narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md:set_created:2026-03-16", + "manufacturer-price-concessions-in-exchange-for-coverage-expansion-is-a-novel-policy-mechanism-bypassing-traditional-cms-rulemaking.md:set_created:2026-03-16" + ], + "rejections": [ + "narrow-eligibility-targeting-high-risk-patients-makes-glp-1-coverage-cost-effective-under-capitation-despite-high-drug-costs.md:missing_attribution_extractor", + "manufacturer-price-concessions-in-exchange-for-coverage-expansion-is-a-novel-policy-mechanism-bypassing-traditional-cms-rulemaking.md:missing_attribution_extractor" + ] + }, + "model": "anthropic/claude-sonnet-4.5", + "date": "2026-03-16" +} \ No newline at end of file diff --git a/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md b/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md index 4b112ae5..c8e88c91 100644 --- a/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md +++ b/inbox/archive/2025-11-06-trump-novo-lilly-glp1-price-deals-medicare.md @@ -7,9 +7,13 @@ date: 2025-11-06 domain: health secondary_domains: [internet-finance] format: news -status: unprocessed +status: enrichment priority: high tags: [glp-1, drug-pricing, medicare, policy, trump-administration, market-structure] +processed_by: vida +processed_date: 2026-03-16 +enrichments_applied: ["GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035.md", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics.md", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md"] +extraction_model: "anthropic/claude-sonnet-4.5" --- ## Content @@ -45,3 +49,12 @@ On November 6, 2025, President Trump announced agreements with Eli Lilly and Nov PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] WHY ARCHIVED: The price reduction + coverage expansion + narrow eligibility criteria fundamentally change the economics analyzed in the existing claim — the "inflationary through 2035" conclusion assumed higher prices and broader population EXTRACTION HINT: Focus on how narrow eligibility (comorbid patients only) changes the cost-effectiveness calculus vs. broad population coverage + + +## Key Facts +- Medicare GLP-1 payment demonstration begins July 2026 +- BALANCE Model in Medicaid begins May 2026 +- BALANCE Model in Medicare Part D begins January 2027 +- Oral Wegovy launches January 2026 at $149-$299/month +- Medicare beneficiary out-of-pocket maximum for tirzepatide is $50/month starting April 2026 +- Approximately 10% of Medicare beneficiaries expected to be eligible under comorbidity criteria